Postprandial dyslipidaemia and diabetes: Mechanistic and therapeutic aspects

Current Opinion in Lipidology

Volumn 23, Issue 4, 2012, Pages 303-309

  Pang, Jing ^a   Chan, Dick C ^a   Barrett, P Hugh R ^a   Watts, Gerald F ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

diabetes; mechanisms; postprandial dyslipidaemia; therapy

Indexed keywords

ALOGLIPTIN; ATORVASTATIN; DOCOSAHEXAENOIC ACID; EXENDIN 4; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; INSULIN; LIPID; LIPOPROTEIN; LIRAGLUTIDE; NICOTINIC ACID; OMEGA 3 FATTY ACID; PITAVASTATIN; SAXAGLIPTIN; SIMVASTATIN; SITAGLIPTIN;

ATHEROGENESIS; DIABETES MELLITUS; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG MEGADOSE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GLYCEMIC CONTROL; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; POSTPRANDIAL DYSLIPIDEMIA; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW;

ATHEROSCLEROSIS; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; HUMANS; POSTPRANDIAL PERIOD;

EID: 84863986423     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328354c790     Document Type: Review

References (94)

1. Turner RC, Millns H, Neil HAW, et al. Risk factors for coronary artery disease in noninsulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). Br Med J 1998; 316:823.
2. Watts GF, Karpe F. Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient. Heart 2011; 97:350-356.
3. Fruchart JC, Sacks FM, Hermans MP, et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diabet Vasc Dis Res 2008; 5:319-335.
4. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46:733-749.
5. Kindel T, Lee DM, Tso P. The mechanism of the formation and secretion of chylomicrons. Atheroscler Suppl 2010; 11:11-16.
6. Xiao C, Lewis GF. Regulation of chylomicron production in humans. Biochim Biophys Acta 2012; 1821:736-746.
7. Duez H, Lamarche B, Valé ro R, et al. Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans. Circulation 2008; 117:2369-2376.
8. Adiels M, Matikainen N, Westerbacka J, et al. Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity. Atherosclerosis 2012; 222:222-228.
9. Pavlic M, Xiao C, Szeto L, et al. Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids. Diabetes 2010; 59:580-587.
10. Nogueira JP, Maraninchi M, Bé liard S, et al. Absence of acute inhibitory effect of insulin on chylomicron production in type 2 diabetes. Arterioscler Thromb Vasc Biol 2012; 32:1039-1044.
11. Laatsch A, Merkel M, Talmud PJ, et al. Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance. Atherosclerosis 2009; 204:105-111.
12. Ng TWK, Watts GF, Farvid MS, et al. Adipocytokines and VLDL Metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes 2005; 54:795-802.
13. Annuzzi G, Bozzetto L, Patti L, et al. Type 2 diabetes mellitus is characterized by reduced postprandial adiponectin response: a possible link with diabetic postprandial dyslipidemia. Metab Clin Exp 2010; 59:567-574.
14. Johansen CT, Hegele RA. Allelic and phenotypic spectrum of plasma triglycerides. Biochim Biophys Acta 2012; 1821:833-842.
15. Perez-Martinez P, Delgado-Lista J, Perez-Jimenez F, Lopez-Miranda J. Update on genetics of postprandial lipemia. Atheroscler Suppl 2010; 11:39-43.
16. The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302:1993-2000.
17. Nordestgaard BG, Langsted A, Freiberg JJ. Nonfasting hyperlipidemia and cardiovascular disease. Curr Drug Targets 2009; 10:328-335.
18. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298:299-308.
19. Langsted A, Nordestgaard BG. Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study. Clin Chem 2011; 57:482-489.
20. van Dieren S, Nö thlings U, van der Schouw YT, et al. Nonfasting lipids and risk of cardiovascular disease in patients with diabetes mellitus. Diabetologia 2011; 54:73-77.
21. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008; 118:993-1001.
22. Reyes-Soffer G, Holleran S, Karmally W, et al. Measures of postprandial lipoproteins are not associated with coronary artery disease in patients with type 2 diabetes mellitus. J Lipid Res 2009; 50:1901-1909.
23. Cavalot F, Pagliarino A, Valle M, et al. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up. Diab Care 2011; 34:2237-2243.
24. Teno S, Uto Y, Nagashima H, et al. Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes. Diab Care 2000; 23:1401-1406.
25. Mori Y, Itoh Y, Komiya H, Tajima N. Association between postprandial remnant-like particle triglyceride (RLP-TG) levels and carotid intima-media thickness (IMT) in Japanese patients with type 2 diabetes. Endocrine 2005; 28:157-163.
26. Hu Y, LiuW, Huang R, Zhang X. Postchallenge plasma glucose excursions, carotid intima-media thickness, and risk factors for atherosclerosis in Chinese population with type 2 diabetes. Atherosclerosis 2010; 210: 302-306.
27. Valdivielso P, Puerta S, Rioja J, et al. Postprandial apolipoprotein B48 is associated with asymptomatic peripheral arterial disease: a study in patients with type 2 diabetes and controls. Clinica Chimica Acta 2010; 411:433-437.
28. Nakajima K, Nakano T, Tanaka A, et al. Particle size of apoB48 carrying lipoproteins in postprandial plasma. Atheroscler Suppl 2010; 11:83-183.
29. Nakajima K, Nakano T, Tokita Y, et al. Postprandial lipoprotein metabolism; VLDL vs chylomicrons. Clinica Chimica Acta 2011; 412:1306-1318.
30. Nakajima K, Nakano T, Tokita Y, et al. The characteristics of remnant lipoproteins in the fasting and postprandial plasma. Clinica Chimica Acta 2012; 413:1077-1086.
31. Bermudez B, Lopez S, Varela LM, et al. Triglyceride-rich lipoprotein regulates apob48 receptor gene expression in human THP-1 monocytes and macrophages. J Nutr 2012; 142:227-232.
32. Scheffer PG, Tushuizen ME, Vermue HPA, et al. Effect of three consecutive meals on the physicochemical properties of HDL and LDL in individuals with the metabolic syndrome and patients with type 2 diabetes. Eur J Clin Nutr 2011; 65:1242-1249.
33. Zheng XY, Liu L. Remnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthase. J Lipid Res 2007; 48:1673-1680.
34. Alipour A, van Oostrom AJ, Izraeljan A, et al. Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler Thromb Vasc Biol 2008; 28:792-797.
35. Al-Aubaidy HA, Jelinek HF. Oxidative DNA damage: antioxidant response in postprandial hyperglycaemia in type 2 diabetes mellitus. Br J Diab Vasc Dis 2011; 11:87-91.
36. Neri S, Calvagno S, Mauceri B, et al. Effects of antioxidants on postprandial oxidative stress and endothelial dysfunction in subjects with impaired glucose tolerance and type 2 diabetes. Eur J Nutr 2010; 49:409-416.
37. Hamilton SJ, Chew GT, Watts GF. Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus. Diab Vasc Dis Res 2007; 4:89-102.
38. Chan DC, Wong ATY, Yamashita S, Watts GF. Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: Effect of fenofibrate treatment. Atherosclerosis 2012; 221:484-489.
39. Klop B, Proctor SD, Mamo JC, et al. Understanding postprandial inflammation and its relationship to lifestyle behaviour and metabolic diseases. Int J Vasc Med 2012; 947417.
40. Bell DSH, O'Keefe JH, Jellinger P. Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events? Endocr Pract 2008; 14:112-124.
41. Su JW, Nzekwu MMU, Cabezas MC, et al. Methods to assess impaired postprandial metabolism and the impact for early detection of cardiovascular disease risk. Eur J Clin Invest 2009; 39:741-754.
42. Smith D, Watts GF, Dane-Stewart C, Mamo JCL. Postprandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state. Eur J Clin Invest 1999; 29:204-209.
43. Hogue JC, Lamarche B, Tremblay AJ, et al. Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes. J Lipid Res 2007; 48:1336.
44. Hanada H, Mugii S, Okubo M, et al. Establishment of chemiluminescence enzyme immunoassay for apolipoprotein B-48 and its clinical applications for evaluation of impaired chylomicron remnant metabolism. Clinica Chimica Acta 2012; 413:160-165.
45. Alipour A, Valdivielso P, Elte JWF, et al. Exploring the value of apoB48 as a marker for atherosclerosis in clinical practice. Eur J Clin Invest 2012; (in press)
46. Dominiczak MH, Caslake MJ. Apolipoproteins: metabolic role and clinical biochemistry applications. Ann Clin Biochem 2011; 48:498-515.
47. Van Oostrom AJ, Alipour A, Sijmonsma TP, et al. Comparison of different methods to investigate postprandial lipaemia. Neth J Med 2009; 67:13-20.
48. Miyashita M. Effects of continuous versus accumulated activity patterns on postprandial triacylglycerol concentrations in obese men. Int J Obes 2008; 32:1271-1278.
49. Singhal A, Trilk JL, Jenkins NT, et al. Effect of intensity of resistance exercise on postprandial lipemia. J Appl Physiol 2009; 106:823-829.
50. Ferreira AP, Ferreira CB, Souza VC, et al. The influence of intense intermittent versus moderate continuous exercise on postprandial lipemia. Clinics 2011; 66:535-541.
51. Hurren NM, Eves FF, Blannin AK. Is the effect of prior exercise on postprandial lipaemia the same for a moderate-fat meal as it is for a high-fat meal? Br J Nutr 2011; 105:506-516.
52. Phillips LK, Peake JM, Zhang X, et al. The effect of a high-fat meal on postprandial arterial stiffness in men with obesity and type 2 diabetes. J Clin Endocrinol Metab 2010; 95:4455-4459.
53. Harte AL, Varma MC, Tripathi G, et al. High fat intake leads to acute postprandial exposure to circulating endotoxin in type 2 diabetic subjects. Diab Care 2012; 35:375-382.
54. Snel M, Jonker JT, Hammer S, et al. Long-term beneficial effect of a 16-week very low calorie diet on pericardial fat in obese type 2 diabetes mellitus patients. Obesity 2012; (in press)
55. Kolovou GD, Anagnostopoulou KK, Salpea KD, et al. The effect of statins on postprandial lipemia. Curr Drug Targets 2007; 8:551-560.
56. Kolovou GD, Kostakou PM, Anagnostopoulou KK, Cokkinos DV. Therapeutic effects of fibrates in postprandial lipemia. Am J Cardiovasc Drugs 2008; 8:243-255.
57. Nagashima H, Endo M. Pitavastatin prevents postprandial endothelial dysfunction via reduction of the serum triglyceride level in obese male subjects. Heart Vessels 2011; 26:428-434.
58. Ceriello A, Taboga C, Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short-and long-term simvastatin treatment. Circulation 2002; 106:1211.
59. Ceriello A, Assaloni R, Da Ros R, et al. Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in type 2 diabetic patients. Circulation 2005; 111:2518-2524.
60. Rosenson RS, Wolff DA, Huskin AL, et al. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diab Care 2007; 30:1945-1951.
61. Watts GF, Barrett PHR, Ji J, et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003; 52:803-811.
62. Bilz S, Wagner S, Schmitz M, et al. Effects of atorvastatin versus fenofibrate on apolipoprotein B-100 and apolipoprotein AI kinetics in mixed hyperlipidemia. J Lipid Res 2004; 45:174-185.
63. Rosenson RS, Helenowski IB. Fenofibrate abrogates postprandial blood viscosity among hypertriglyceridemia subjects with the metabolic syndrome. Diab Metab Syndr Clin Res Rev 2009; 3:17-23.
64. Plaisance EP, Mestek ML, Mahurin AJ, et al. Postprandial triglyceride responses to aerobic exercise and extended-release niacin. Am J Clin Nutr 2008; 88:30-37.
65. Plat J, Jellema A, Ramakers J, Mensink RP. Weight loss, but not fish oil consumption, improves fasting and postprandial serum lipids, markers of endothelial function, and inflammatory signatures in moderately obese men. J Nutr 2007; 137:2635-2640.
66. Maki KC, Lawless AL, Kelley KM, et al. Prescription omega-3-acid ethyl esters reduce fasting and postprandial triglycerides and modestly reduce pancreatic [beta]-cell response in subjects with primary hypertriglyceridemia. Prostaglandins Leukot Essent Fatty Acids 2011; 85:143-148.
67. Jiménez-Gómez Y, Marín C, Peé rez-Martínez P, et al. A low-fat, high-complex carbohydrate diet supplemented with long-chain (n-3) fatty acids alters the postprandial lipoprotein profile in patients with metabolic syndrome. J Nutr 2010; 140:1595-1601.
68. Slivkoff-Clark KM, James AP, Mamo JCL. The chronic effects of fish oil with exercise on postprandial lipaemia and chylomicron homeostasis in insulin resistant viscerally obese men. Nutr Metab 2012; 9: (in press)
69. Masuda D, Nakagawa-Toyama Y, Nakatani K, et al. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia. Eur J Clin Invest 2009; 39:689-698.
70. Tremblay AJ, Lamarche B, Hogue JC, Couture P. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. J Lipid Res 2009; 50:1463-1471.
71. Sandoval JC, Nakagawa-Toyama Y, Masuda D, et al. Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia. J Atheroscl Thromb 2010; 17:914-924.
72. Yunoki K, Nakamura K, Miyoshi T, et al. Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. Atherosclerosis 2011; 217:486-491.
73. Kotani K, Sakane N, Taniguchi N. Effect of ezetimibe on remnant-like particle cholesterol in subjects with metabolic syndrome. Med Princ Pract 2011; 21:134-138.
74. Chan DC, Watts GF, Gan SK, et al. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulinresistant obese subjects on a weight loss diet. Diab Care 2010; 33:1134-1139.
75. Lee SH, Park S, Kang SM, et al. Effect of atorvastatin monotherapy and lowdose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipedemia. J Cardiovasc Pharmacol Ther 2011; 17:65-71.
76. Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, Visseren FLJ. The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. Atherosclerosis 2009; 202:216-224.
77. Bozzetto L, Annuzzi G, Corte GD, et al. Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. Atherosclerosis 2011; 217:142-148.
78. Schwartz SL, Ratner RE, Kim DD, et al. Effect of exenatide on 24-h blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. Clin Ther 2008; 30:858-867.
79. Schwartz EA, Koska J, Mullin MP, et al. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis 2010; 212:217-222.
80. Koska J, Schwartz EA, Mullin MP, et al. Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diab Care 2010; 33:1028-1030.
81. Flint A, Kapitza C, Hindsberger C, Zdravkovic M. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther 2011; 28:213-226.
82. Fineman MS, Cirincione BB, Maggs D, Diamant M. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diab Obes Metab 2012; (in press)
83. Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88:2719-2725.
84. Tremblay AJ, Lamarche B, Deacon CF, et al. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diab Obes Metab 2011; 13:366-373.
85. Barnett AH, Charbonnel B, Donovan M, et al. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin 2012; 28:513-523.
86. Eliasson B, Mö ller-Goede D, Eeg-Olofsson K, et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia 2012; 55:915-925.
87. Anagnostis P, Athyros VG, Adamidou F, et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diab Obes Metab 2011; 13:302-312.
88. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32:1345-1361.
89. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a Scientific Statement From the American Heart Association. Circulation 2011; 123:2292-2333.
90. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 2011; 32:1769-1818.
91. American Diabetes Association. Standards of medical care in diabetes: 2012. Diab Care 2012; 35:S11-S63.
92. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk. Diab Care 2008; 31:811-822.
93. Kolovou GD, P Mikhailidis D, Kovar J, et al. Assessment and clinical relevance of nonfasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011; 9:258-270.
94. The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255-2267.